Navigation Links
SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
Date:1/6/2009

company developing protein-based pharmaceuticals using its proprietary protein production technology. This technology enables the production of therapeutic proteins in plant seeds by genetically enhancing the safflower plant. SemBioSys' lead pharmaceutical candidates are recombinant human insulin, which is intended to serve the rapidly expanding global diabetes market, and Apo AI(Milano). Apo AI(Milano) is a variant of Apo AI, the major protein associated with high density lipoprotein (HDL), or "good cholesterol", whose function is to remove excess cholesterol from arteries. In addition to its pharmaceutical products, SemBioSys' subsidiary, Botaneco Specialty Ingredients Inc., is selling oleosome-based all natural products in the global personal care ingredient market. More information is available and can be accessed at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions and market size, the acceptance of an IND by the FDA in respect of clinical studies, the submission of a CTA to the appropriate European authorities, the successful initiation and timely and successful completion of clinical studies, the fact that Apo AI is currently a development stage drug, the establishment of corporate alliances, the impact of competitive products and pricing, new pro
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. SemBioSys begins phase I/II trial of insulin produced in plant seeds
2. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
3. SemBioSys announces second quarter 2008 financial and operational results
4. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
5. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
6. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
7. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
8. SemBioSys announces first quarter 2008 financial and operational results
9. SemBioSys receives milestone payments from AVAC Ltd.
10. SemBioSys initiates toxicology study for safflower-produced insulin
11. SemBioSys announces 2007 financial and operational results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/25/2015)... Francisco, CA (PRWEB) March 25, 2015 ... Support for Novel Mechanism of Action in Neuromuscular ... 25, 2015 – Cytokinetics, Incorporated (Nasdaq: CYTK) announced ... fast skeletal muscle troponin activator tirasemtiv in the ... a Phase IIa “Evidence of Effect” or hypothesis-generating ...
(Date:3/25/2015)... and the HAGUE, Netherlands , March ... of LES Stimulation therapy for chronic gastro-esophageal reflux disease ... Surgery [ Surgery . 2015; 157(3):556-567 ], ... minimally-invasive therapy. The study included 25 ... 11 years and taking prescribed daily proton pump inhibitor ...
(Date:3/25/2015)... COLLEGE PARK, Md. , March 25, 2015 ... of two years of intense research by scientists ... University of Maryland and represent a breakthrough in ... an assistant professor in the Department of Animal & ... faculty research assistant in ANSC, successfully produced genome-edited ...
(Date:3/25/2015)... , March 25, 2015  CASI Pharmaceuticals, Inc. ... the acquisition, development and commercialization of innovative therapeutics addressing ... market with a commercial focus on China ... 2 trial of its target therapy drug candidate ENMD-2076 ... of Chinese Academy of Medical Sciences in ...
Breaking Biology Technology:Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 2Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 3Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 4Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 5Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia Gravis 6EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 2EndoStim LES Stimulation therapy demonstrates long term safety and efficacy results in treating reflux patients 3University of Maryland Researchers Successfully Produce Genome-edited Pigs Using Revolutionary Technology 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 4CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 5
... Informed Medical Communications (IMC), a leading provider of ... announced the appointment of Kerry Crawford to the ... this critical role, Kerry will lead operations and ... relationship management systems. This key addition is ...
... sweeteners partner to produce world,s first probiotic-enhanced ... baking aisleINDIANAPOLIS, March 3 Ganeden ... the patented probiotic strain GanedenBC30, today announced ... , an Indianapolis-based leading innovator of health ...
... Inc.,(OTC Bulletin Board: CLXS), a leading developer of ... launch of the world,s first,CTSA Experts Platform drawing ... more than 60,000 life science researchers. The platform ... of the Clinical Translational Science,Awards (CTSA,s) from the ...
Cached Biology Technology:Informed Medical Communications Appoints New Senior Manager, Strategic Operations 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 2Ganeden Biotech and Heartland Sweeteners to Produce Probiotic Sweetener 3Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 2Collexis Connects the NIH Clinical and Translational Science Award Programs with CTSA Expert Platform 3
(Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
(Date:3/10/2015)... NEW YORK , March 10, 2015  Continuing ... and the Unexpected, Hammacher Schlemmer introduces The Eye ... user,s identity before granting access to secure websites or ... trusted to verify travelers at international borders, the device ... 240 distinctive pattern points of the iris, converting them ...
(Date:3/10/2015)... Utah , March 10, 2015   Tute ... interpretation, has been selected by next-generation sequencing company ... of whole exome and targeted gene panel interpretation. ... provider, has adopted the most current technologies to support ... genetic research. The company offers two types of exome ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
... will gather in Maputo, Mozambique, 21-24 October, for the ... Science (ICSU)the first time an ICSU GA will be ... scientists from around the world will come together at ... can contribute to solving some of the most pressing ...
... green may be heart healthy if the green ... at Penn State who conducted the first study ... "We investigated mechanisms of action to explain the ... K. Gebauer, recent Penn State Ph.D. recipient, currently ...
... Boulder, CO, USA Counting on wetlands restoration projects ... is likely to be a "losing battle" that provides ... for their future, says a researcher from Western Carolina ... Gulf of Mexico this fall, the media has been ...
Cached Biology News:Global science community to gather in Mozambique 2Researchers study how pistachios may improve heart health 2Wetlands restoration not a panacea for Louisiana coast 2Wetlands restoration not a panacea for Louisiana coast 3
Human peripheral blood CD19+ B cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Monocytes, B Cells, NK Cells and Stem Cells...
Umbilical cord blood mononuclear cells, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood MNCs and T Cells...
Human plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Umbilical cord blood basophils, For immunohistochemistry (IHC)...
Biology Products: